Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Cited In for PubMed (Select 11177073)

1.

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.

Al-Alaiyan S, Pollack P, Notario GF.

Drugs Context. 2015 Feb 27;4. pii: 212270. doi: 10.7573/dic.212270. eCollection 2015.

2.

Bronchiolitis: Recommendations for diagnosis, monitoring and management of children one to 24 months of age.

Friedman JN, Rieder MJ, Walton JM; Canadian Paediatric Society, Acute Care Committee, Drug Therapy and Hazardous Substances Committee.

Paediatr Child Health. 2014 Nov;19(9):485-98. English, French.

3.

Trends in bronchiolitis hospitalizations in the United States, 2000-2009.

Hasegawa K, Tsugawa Y, Brown DF, Mansbach JM, Camargo CA Jr.

Pediatrics. 2013 Jul;132(1):28-36. doi: 10.1542/peds.2012-3877. Epub 2013 Jun 3.

4.

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children.

Nair H, Verma VR, Theodoratou E, Zgaga L, Huda T, Simões EA, Wright PF, Rudan I, Campbell H.

BMC Public Health. 2011 Apr 13;11 Suppl 3:S30. doi: 10.1186/1471-2458-11-S3-S30. Review.

5.

The use of a neonatal mouse model to study respiratory syncytial virus infections.

Cormier SA, You D, Honnegowda S.

Expert Rev Anti Infect Ther. 2010 Dec;8(12):1371-80. doi: 10.1586/eri.10.125. Review.

6.

A fluorescence polarization assay using an engineered human respiratory syncytial virus F protein as a direct screening platform.

Park M, Matsuura H, Lamb RA, Barron AE, Jardetzky TS.

Anal Biochem. 2011 Feb 15;409(2):195-201. doi: 10.1016/j.ab.2010.10.020. Epub 2010 Nov 5.

7.

Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease.

Ripple MJ, You D, Honnegowda S, Giaimo JD, Sewell AB, Becnel DM, Cormier SA.

J Immunol. 2010 Oct 15;185(8):4804-11. doi: 10.4049/jimmunol.1000484. Epub 2010 Sep 22.

8.

Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology.

Tregoning JS, Schwarze J.

Clin Microbiol Rev. 2010 Jan;23(1):74-98. doi: 10.1128/CMR.00032-09. Review.

9.

Pharmacological management of acute bronchiolitis.

Wright M, Mullett CJ, Piedimonte G.

Ther Clin Risk Manag. 2008 Oct;4(5):895-903.

10.

Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Mejías A, Chávez-Bueno S, Ríos AM, Saavedra-Lozano J, Fonseca Aten M, Hatfield J, Kapur P, Gómez AM, Jafri HS, Ramilo O.

Antimicrob Agents Chemother. 2004 May;48(5):1811-22.

11.

Kawasaki syndrome hospitalizations and associated costs in the United States.

Belay ED, Holman RC, Maddox RA, Foster DA, Schonberger LB.

Public Health Rep. 2003 Sep-Oct;118(5):464-9.

12.

Detection of human respiratory syncytial virus in respiratory samples by LightCycler reverse transcriptase PCR.

Whiley DM, Syrmis MW, Mackay IM, Sloots TP.

J Clin Microbiol. 2002 Dec;40(12):4418-22.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk